The vasculitic neuropathies
- 1 October 2012
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Neurology
- Vol. 25 (5), 573-585
- https://doi.org/10.1097/wco.0b013e3283580432
Abstract
Vasculitic neuropathy is a heterogeneous disorder that usually occurs in systemic diseases, but less commonly appears as nonsystemic vasculitic neuropathy (NSVN). This review is intended to highlight recent developments in the field of vasculitic neuropathies. A Peripheral Nerve Society guideline provides data-driven consensus recommendation on classification of vasculitic neuropathies and diagnosis/treatment of NSVN. NSVN is sometimes accompanied by subclinical inflammation of adjacent skin. Amyotrophic lateral sclerosis with sensory involvement can mimic NSVN. Systemic vasculitides with neuropathy include polyarteritis nodosa, microscopic polyangiitis (MPA), rheumatoid vasculitis, Churg-Strauss syndrome (CSS), and hepatitis C-related mixed cryoglobulinemic vasculitis (MCV). At autopsy, MPA affects limb nerves diffusely, with maximal damage in proximal/middle segments. CSS can be accompanied by antineutrophil cytoplasmic antibodies (ANCAs), but most patients with neuropathy lack ANCAs. Cryoglobulinemic neuropathies are usually caused by vasculitis, irrespective of phenotype. Two randomized trials revealed rituximab to be noninferior to cyclophosphamide for inducing remission in ANCA-associated vasculitis. Many reports also document efficacy of rituximab in MCV. Consensus guidelines on NSVN should be evaluated prospectively. MPA-associated vasculitic neuropathy results from vasculitic lesions distributed diffusely throughout peripheral extremity nerves. Rituximab is effective for ANCA-associated and cryoglobulinemic vasculitis with neuropathy.Keywords
This publication has 138 references indexed in Scilit:
- A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus–associated cryoglobulinemic vasculitisArthritis & Rheumatism, 2011
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesHepatology, 2011
- Plasma Exchange for Renal Vasculitis and Idiopathic Rapidly Progressive Glomerulonephritis: A Meta-analysisAmerican Journal of Kidney Diseases, 2011
- Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitisArthritis Care & Research, 2011
- Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody–associated vasculitis: A meta‐analysisArthritis Care & Research, 2010
- Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisNew England Journal of Medicine, 2010
- An approach to the diagnosis and management of systemic vasculitisClinical and Experimental Immunology, 2010
- Diagnosis, management, and treatment of hepatitis C: An updateHepatology, 2008
- Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studiesAnnals Of The Rheumatic Diseases, 2006
- Fulminant hepatitis caused by hepatitis C virus during treatment for multiple sclerosisThe Esophagus, 1996